LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Newsletter Volume 3 Issue 11 LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Home LymeNet Newsletter Library

Volume: 3
Issue: 11
Date: 19-Jul-95


Table of Contents:

I.    LYMENET: Vancouver LD Conference Notes - Part 2
II.   About The LymeNet Newsletter


Newsletter:

***********************************************************************
*                  The National Lyme Disease Network                  *
*                         LymeNet Newsletter                          *
***********************************************************************


IDX#                Volume 3 - Number 11 - 7/19/95
IDX#                            INDEX
IDX#
IDX#  I.    LYMENET: Vancouver LD Conference Notes - Part 2
IDX#  II.   About The LymeNet Newsletter
IDX#



I.    LYMENET: Vancouver LD Conference Notes - Part 2
-----------------------------------------------------
Sender: Lloyd E. Miller, DVM <LloydEM@aol.com>


Notes from the VIII Annual Lyme Disease Foundation Scientific
Conference on Lyme Borreliosis and other Spirochetal and Tick-Borne
Diseases - Held April 28-29 1995 -- at Vancouver, British Columbia,
Canada.


Part 2

Prepared by Lloyd E. Miller, DVM

Every effort has been made to be accurate.  Please report any
additions or corrections.  Always confirm drug doses and names of
medications with another source before using.



18. Detection of Borrelia burgdorferi sequences in clinical
specimens by a PCR capture assay - M.Manak, M.D.


The development of a PCR test was described. In this test which was
used on samples of urine, blood, serum, joint fluid and CSF it was
felt that whole blood and serum were a more reliable indicator of
active infection than was urine.  It is noted that 89% of patients
with a positive PCR also had other positive serologic evidence
(WB, ELISA, IgM capture) of Lyme disease yet it was felt that PCR
was a valuable adjunct to the other tests.


19. Detection of Borrelia burgdorferi-DNA in urine from patients
with Lyme borreliosis - B. Schmidt, Ph.D.


A PCR test is described which was used to test urine for the presence
of Bb-DNA.  Of 90 EM patients 80 (88.9%) had positive urine PCR
tests.  In comparison serology was reactive for IgG in 11.1 to
16.7% and only 2 of 66 tested sera had antibodies to p39 antigen.
IgM was detected in 6 to 40% depending on the test used.  The
conclusion made was that by using this urine PCR test detection of
Bb infection can be improved dramatically.  This work was done in
Austria.


20. A Solid phase ELISA-antigen detection system for LD - R.C.
Tilton, Ph.D.


The development of a urine test to detect Bb antigens in urine using
an ELISA system was described.  It was said to be able to detect
less than 10 organisms.  This test may be commercially available in
a few months.  Also being investigated is the use of this test with
other body fluids.


An interesting rhetorical question was asked by Dr. Tilton: Is it the
antibody tests that are not reliable or the LD patient's antibody
that is not reliable?


21. Surrogate markers of active infection in Lyme disease -
S. Schutzer, M.D.


A specific antibody may be found bound to an infectious agent (immune
complex), especially in early and during active infection.  That this
could be occurring in Lyme disease was tested.  Complexed antibody to
Bb was found in 10 of 11 very early cases, 55 of 56 symptomatic
patients, 0 of 50 healthy controls, 2 of 50 patients from endemic
areas with other diseases including those likely to have elevated
levels of immune complexes, 13 of 13 persistently seronegative
patients who had EM and a subset of 4 of 4 who were also positive on
a T cell proliferative assay to Bb, and 0 of 8 patients who had
recovered.  In early acute cases complexed IgM was the first antibody
to be detected.  This study suggested that testing for complexed
antibody may help improve the diagnosis of LD by testing.


22. New tools in the diagnosis of neurologic Lyme disease -
P.K. Coyle, M.D.


Diagnosis of neurologic disease caused by Bb can be very difficult.
Many of the tests currently being used were discussed (basic CSF
tests, CSF culture, antigen detection, PCR, intrathecal antibody
detection, immune complex detection, neuroimaging, neurophysiologic,
neuropsychiatric testing).  All have short comings.  *No single test
can be relied upon to confirm or deny a diagnosis of CNS Lyme
disease*.  This does not mean the testing should not be done but
that the results must be interpreted in the light of the known
problems inherent in the tests.  Comment was made that intrathecal
antibody production can not be used to diagnose LD in North America
because intrathecal antibodies are not often produced.  When
oligoclonal bands are found consider MS before LD.  Significant
slowing in reaction times is seen in LD.  Also affected are
attention and learning retrieval.  Nerve conduction times can be
slower than normal.


23. Morphologic diversity of Borreliae: a review - A. McDonald, M.D.

Dr. McDonald showed an impressive number of various forms of
spirochetes as they appear in tissues described by various
pathologist.  To visualize these forms requires a dark field
microscope in many cases.  Comment was made that unfortunately most
of these microscopes have been taken out of service and the
expertise to use them is being lost.


[Comment - Several promising tests were described at this meeting.
Still, none of them is the gold standard.  It would seem
reasonable to do a panel of tests of various types in an effort to
make a laboratory confirmation of Lyme disease. The test results
must be interpreted by physicians knowledgeable about the inherent
problems of each test.  Even then some cases will be missed.
*Lyme disease is still a clinical diagnosis.*]



CLINICAL MANIFESTATIONS OF LYME DISEASE

24. Clinical presentations of Lyme borreliosis in lower Midwest -
E. Masters, M.D.


A report on the on going saga of "Master's disease".  Still no
agreement from the CDC that Master's and Lyme diseases are one
and the same.  The possibility that they are both clinically
indistinguishable but caused by variants of similar organisms
exists.  The borrelia found is not typical of North American forms
described so far.  Stay tuned!


Differentiation of EM vs. brown recluse spider bite was demonstrated.
Spider bite is extremely painful.  The bite is not usually in the
center of the lesion.  Spider bite displays the red (erythema)
White (ischemia) and blue (necrosis) sign.


Dr. Masters made the point that "Hypochondria does not develop out of
the blue in a 45 year old with no previous history of disease."


25. Lyme arthritis in British Columbia - G. Price, M.D

The first known locally acquired case of Lyme arthritis in B.C. was
described.  Comment was made that compared to other areas there are
few cases of arthritis caused by Lyme disease in British Columbia.
No explanation is yet offered.


26. Cardiovascular manifestations of Lyme Disease  - B. McManus, M.D.

A high frequency of electrophysiological perturbations has been
documented in LD.  First, second and third degree heart block are
described with third degree being most common.  Patients with Lyme
carditis may exhibit presyncope, syncope (fainting), palpitations,
shortness of breath, chest pain and electrocardiographic
abnormalities.  In some patients a *temporary* pace maker may be
required.  Rarely is there permanent heart muscle damage or chronic
heart disease as the result of Lyme disease.


27. Lyme disease cases in the Lower Mainland - E. Murakami

A case of Lyme disease acquired within the boundaries of B.C. was
described.


A new technique for removal of ticks from patients was demonstrated.
The removal method involves the injection of Xylocaine intradermally
producing a bubble of liquid which produces hydrostatic pressure at
the site of the bite causing the tick to release and fall off.


28. Acrodermatitis chronica atrophicans - R, Scrimenti. M.D.

ACA was describe.  It is primarily seen in Europe but has been
described in North American patients.  It is an excellent example of
prolonged latency and chronic infection with Bb.  Bb titers in these
patients are usually high.  The usual treatment is doxycycline.
If neurologic and/or arthritic complications are present then Benzyl
penicillin IV and oral doxycycline are then used to treat.


29. Symptoms and characteristics of chronic LD patients -
Smithon, Ph.D., I. Vanderhoof, Ph.D.


Information is based on studies of questionnaires provided to the Lyme
Disease Foundation by patients.  Symptom patterns of Lyme disease
showed no difference based on geographic location.  Symptom patterns
were also the same whether the patient was diagnosed by a general
practitioner or a  specialist.  Becoming symptom free seems to
depend on getting *early* treatment.  The earlier the diagnosis is
made and the earlier treatment is administered the more favorable the
outcome.  The more severe the EM rash is the more likely it is that
the patient will recover with no residual symptoms.  It is presumed
that the more severe the rash the more likely it is that a patient
will seek and receive medical attention.  Profound exhaustion appears
to be a marker indicating that recovery is less likely.  Continuous
symptoms indicate continuing disease and is also indicative of a
poorer prognosis for full recovery.  Severity of symptoms, except
EM rash, is not a good indicator of prognosis.  The information
presented was considered preliminary.  However, this does appear to

agree with anecdotal information currently available.  A poster on
this topic was also presented by Robert C. Smithson and Kathryn A.
Robbins.


CHRONIC/PERSISTING LYME BORRELIOSIS

30. Antibiotic resistance in spirochetes - J. Davis, M.D.

Apparently there is no work on antibiotic resistance by Bb. Mechanisms
of microbial resistance to antibiotics were discussed in general
terms.  Reasons for resistance include: failure of the antibiotic to
enter the microbe; active removal of the antibiotic from the microbe
before it can cause damage; sequestration of the drug within the
microbe; detoxification of the antibiotic by the microbe; damage
caused is repaired resulting in no harm; genetic gene transfer
mechanisms both acquired and mutation; target on the microbe is
missing, modified or amplified.  His best guess in the case of Bb
would be the active removal mechanism.  


31. Spectrum of antibiotic-responsive menigoencephalomyelitides - K.B.
Liegner, M.D.


This presentation was to document four very difficult and severe cases
histories of Lyme disease, one of which resulted in death.
Unfortunately there was not enough time for Dr. Liegner to present
these cases.  It is hoped he will do so in another forum and in the
literature because this information is very important to the
understanding of how very serious this disease can be.  What
information he was able to present (including a short video)
demonstrated how very difficult it can be to diagnose LD in severely
ill patients with no serologic evidence of the disease.


32. Management chronic Lyme disease - J. J. Burrascano, Jr., M.D.

Citing several literature reports to make his point, Dr. Burrascano
said "It is truly a myth that a patient with disseminated disease is
cured with four weeks of antibiotic therapy."  He enumerated several
reasons why Bb resists eradication; latency and S-layers,
localization in privileged sites (intracellular and intraocular),
inadequate understanding of how antibiotics kill Bb, ignoring the
pharmacologic principles of antibiotic half lives, cell penetration
and CSF and tissue levels.  He made and strongly emphasized the
need to do serum peek and trough levels whenever oral antibiotics are
used.  The peek level should be in the mid-teens and the trough
level *must* be above three.  In his studies he has documented 100
fold variability in serum ampicillin levels in patients matched by
age, body size and drug dose.  Unless oral antibiotics are absorbed
from the GI tract in sufficient amount to produce serum and tissue
levels high enough to inhibit Bb there is little or no chance the
antibiotic will be effective.  He commented that intramuscular

benzathine penicillin has been shown to be unexpectedly effective.

Also, IV doxycycline has been more effective than oral doxycycline.
He also pointed out that IV antibiotics have big advantages in
efficacy over oral regimens.  By using strategies such as interrupted
and pulse dosing IV antibiotic use has been quite safe and effective.
His studies have shown that many patients with resistant infections
have deficiencies in B, T, and/or killer cell function.  If these
abnormalities can be corrected then treatment response improves.
The stated end point of treatment is when the patient is *totally*
free of symptoms.


His suggested that the starting oral dose of doxycycline should now
be 300mg per day.  Do peak and trough levels and adjust the dose
accordingly.  He said Augmentin is not an appropriate antibiotic
choice for use in LD.  To reduce the side effects if IV Rocephin
he suggested a dosage regime of 5 days on and 2 days off using up
to 4 grams per day.  Dosage for benzathine penicillin was suggested
to be 1.2 million units once or twice weekly long term.  It was
suggested that vitamin B-12 levels be checked and corrected if
they are low.


To help improve T cell function he suggested Sinequan 5 to 50 mg
daily.


[Comment -  Dr. Paul LaVoie advocated the same end point of
treatment (that is to treat until there are zero symptoms - including
the minor symptoms).  He estimated that if treatment is taken to this
end point the relapse rate is about 10%; otherwise relapse rate
approximates 60%.  Dr. Burrascano noted that copies of his latest
treatment protocols are available from the Lyme Disease Foundation.]



33. Chronic encephalopathy: to treat or not to treat? -
B. Fallon, M.D.


Problems with fatigue, memory, attention, depression and mental
disorganization are features of Lyme encephalopathy.  When a patient
has been treated for several months with antibiotics and still has
problems the following questions must be asked and answered;
1 - Is the diagnosis of Lyme encephalopathy correct?
2 - are there other coexisting problems that could be better treated
(depression, panic disorder, ADD).
3 - Are somatoform features involved (psycogenic seizures).
4 - what has been the previous response to antibiotic treatment?


Preliminary results of a study involving patients who have Lyme
encephalopathy who had received no more than 16 weeks of IV
antibiotic was reported.  The response was assessed in the patients
who received additional course of IV therapy vs. the response in
patients who did not receive additional IV antibiotic.  Patients
who received additional IV antibiotic therapy had a marked
improvement in general health, emotional well being and physical
functioning.  Those who received additional oral antibiotic therapy
or no additional therapy did not have this marked response.
The number of patients in the study is small which may affect the
results.  The study, however, is on going and as the sample size
increases the results will become more reliable.


Comment was also made that IM benzathine penicillin has given some
unexpectedly good results. The suggestion was made that ADD can be
treated with Wellbutrin and stimulants.



=====*=====


II.   ABOUT THE LYMENET NEWSLETTER
-----------------------------------
For the most current information on LymeNet subscriptions,
contributions, and other sources of information on Lyme disease,
please request the LymeNet Resource Guide.  To obtain the Guide,
send a blank message to:      resource-guide@lymenet.org
-----------------------------------------------------------------------
The LymeNet Resource Guide is in Revision:  1.10  
-----------------------------------------------------------------------
LymeNet - The Internet Lyme Disease Information Source
-----------------------------------------------------------------------
Editor-in-Chief: Marc C. Gabriel <a229@Lehigh.EDU>
           FAX: 908-789-0028
Contributing Editors: Carl Brenner <brenner@ldeo.Columbia.EDU>
                     John Setel O'Donnell <jod@Equator.COM>
                     Frank Demarest <76116.2065@CompuServe.COM>
Advisors: Carol-Jane Stolow, Director <carol@lymenet.org>
         William S. Stolow, President <bill@lymenet.org>

         The Lyme Disease Network of New Jersey (908-390-5027)
-----------------------------------------------------------------------
WHEN COMMENTS ARE PRESENTED WITH AN ATTRIBUTION, THEY DO NOT
NECESSARILY REPRESENT THE OPINIONS/ANALYSES OF THE EDITORS.
-----------------------------------------------------------------------
THIS NEWSLETTER MAY BE REPRODUCED AND/OR POSTED ON BULLETIN BOARDS
FREELY AS LONG AS IT IS NOT MODIFIED OR ABRIDGED IN ANY WAY.
-----------------------------------------------------------------------
SEND ALL BUG REPORTS TO a229@Lehigh.EDU
-----------------------------------------------------------------------


Home | Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet


© 1994-1999 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to the Terms of Use.